Add like
Add dislike
Add to saved papers

Modeling the cost of eradicating livestock-associated methicillin-resistant staphylococcus aureus in countries with a high proportion of positive herds.

Due to an increased incidence of human infections, livestock-associated methicillin-resistant Staphylococcus Aureus (LA-MRSA) in pigs and its spread into the human population has been a major public and political issue in Denmark. Similar concerns are also being raised about LA-MRSA in other Western European countries. At a time when the proportion of LA-MRSA-positive pig farms was low, Norway adopted a 'trace and destroy' strategy aimed at keeping LA-MRSA out of the pig population. However, to date, no country with a high proportion of LA-MRSA-positive pig herds has chosen to use an eradication strategy. This study analyses the cost and complexities of conducting an LA-MRSA eradication program in a situation where a large proportion of herds are positive. The total cost of the eradication program was estimated based on the following components: 1) planning, 2) monitoring and testing, 3) cleaning and disinfection, 4) production gains and losses, 5) net reduction in breeding exports, and 6) loss of genetic progress, including the costs of a mitigating caesarean section strategy in breeding herds. Costs were related to the depopulation of 1 million sows, to gilt supply (as this was an important limiting factor during an eradication program in Denmark), and to aggregated losses linked to a temporary halt on breeding progress. Using conservative assumptions, the total eradication costs were estimated at €1.8 billion, broken down into: planning costs (3%), monitoring and testing (6%), cleaning and disinfection (19%), production gains and losses (33%), net loss from breeding exports (19%) and loss of genetic progress (20%). The long-term effects of an LA-MRSA eradication program for Danish pig production were uncertain and were therefore not taken into account in the analysis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app